{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:58:09Z","timestamp":1791899889739,"version":"4.3.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s00228-019-02694-1","type":"journal-article","created":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T15:14:11Z","timestamp":1559402051000},"page":"1219-1226","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Vancomycin population pharmacokinetics for adult patients with sepsis or septic shock: are current dosing regimens sufficient?"],"prefix":"10.1007","volume":"75","author":[{"given":"A. J.","family":"Heffernan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Germano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4061-2063","authenticated-orcid":false,"given":"F. B.","family":"Sime","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason A.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,1]]},"reference":[{"key":"2694_CR1","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1097\/01.CCM.0000194725.48928.3A","volume":"34","author":"JL Vincent","year":"2006","unstructured":"Vincent JL, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H, Moreno R, Carlet J, le Gall JR, Payen D, Sepsis Occurrence in Acutely Ill Patients Investigators (2006) Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 34:344\u2013353","journal-title":"Crit Care Med"},{"key":"2694_CR2","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1097\/01.CCM.0000217961.75225.E9","volume":"34","author":"A Kumar","year":"2006","unstructured":"Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S et al (2006) Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 34:1589\u20131596","journal-title":"Crit Care Med"},{"key":"2694_CR3","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.ijantimicag.2012.10.015","volume":"41","author":"S Zelenitsky","year":"2013","unstructured":"Zelenitsky S, Rubinstein E, Ariano R, Iacovides H, Dodek P, Mirzanejad Y, Kumar A, Cooperative Antimicrobial Therapy of Septic Shock-CATSS Database Research Group (2013) Vancomycin pharmacodynamics and survival in patients with methicillin-resistant Staphylococcus aureus-associated septic shock. Int J Antimicrob Agents 41:255\u2013260","journal-title":"Int J Antimicrob Agents"},{"key":"2694_CR4","doi-asserted-by":"publisher","first-page":"82","DOI":"10.2146\/ajhp080434","volume":"66","author":"M Rybak","year":"2009","unstructured":"Rybak M, Lomaestro B, Rotschafer JC, Moellering R Jr, Craig W, Billeter M, Dalovisio JR, Levine DP (2009) Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 66:82\u201398","journal-title":"Am J Health Syst Pharm"},{"key":"2694_CR5","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.ijantimicag.2005.11.009","volume":"27","author":"I Mohammedi","year":"2006","unstructured":"Mohammedi I, Descloux E, Argaud L, Le Scanff J, Robert D (2006) Loading dose of vancomycin in critically ill patients: 15 mg\/kg is a better choice than 500 mg. Int J Antimicrob Agents 27:259\u2013262","journal-title":"Int J Antimicrob Agents"},{"key":"2694_CR6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/2052-0492-2-31","volume":"2","author":"S Sunder","year":"2014","unstructured":"Sunder S, Jayaraman R, Mahapatra HS, Sathi S, Ramanan V, Kanchi P, Gupta A, Daksh S, Ram P (2014) Estimation of renal function in the intensive care unit: the covert concepts brought to light. J Intensive Care 2:31. \n                    https:\/\/doi.org\/10.1186\/2052-0492-2-31","journal-title":"J Intensive Care"},{"key":"2694_CR7","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1097\/FTD.0b013e31825c4ba6","volume":"34","author":"MN Neely","year":"2012","unstructured":"Neely MN, van Guilder MG, Yamada WM, Schumitzky A, Jelliffe RW (2012) Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R. Ther Drug Monit 34:467\u2013476","journal-title":"Ther Drug Monit"},{"key":"2694_CR8","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s10928-005-0016-4","volume":"33","author":"F Mentre","year":"2006","unstructured":"Mentre F, Escolano S (2006) Prediction discrepancies for the evaluation of nonlinear mixed-effects models. J Pharmacokinet Pharmacodyn 33:345\u2013367","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"2694_CR9","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1007\/s00134-005-2763-5","volume":"31","author":"RP Moreno","year":"2005","unstructured":"Moreno RP, Metnitz PGH, Almeida E, Jordan B, Bauer P, Campos RA, Iapichino G, Edbrooke D, Capuzzo M, le Gall JR, on behalf of the SAPS 3 Investigators (2005) SAPS 3\u2014from evaluation of the patient to evaluation of the intensive care unit. Part 2: development of a prognostic model for hospital mortality at ICU admission. Intensive Care Med 31:1345\u20131355","journal-title":"Intensive Care Med"},{"key":"2694_CR10","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31\u201341","journal-title":"Nephron"},{"key":"2694_CR11","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/0025-5564(72)90003-X","volume":"14","author":"R Jelliffe","year":"1972","unstructured":"Jelliffe R, Jelliffe S (1972) A computer program for estimation of creatinine clearance from unstable serum creatinine levels, age, sex, and weight. Math Biosci 14:17\u201324","journal-title":"Math Biosci"},{"key":"2694_CR12","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1177\/1060028015571163","volume":"49","author":"J Reardon","year":"2015","unstructured":"Reardon J, Lau TT, Ensom MH (2015) Vancomycin loading doses: a systematic review. Ann Pharmacother 49:557\u2013565","journal-title":"Ann Pharmacother"},{"key":"2694_CR13","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s00228-014-1766-y","volume":"71","author":"C Burdet","year":"2015","unstructured":"Burdet C, Pajot O, Couffignal C, Armand-Lefevre L, Foucrier A, Laouenan C et al (2015) Population pharmacokinetics of single-dose amikacin in critically ill patients with suspected ventilator-associated pneumonia. Eur J Clin Pharmacol 71:75\u201383","journal-title":"Eur J Clin Pharmacol"},{"key":"2694_CR14","doi-asserted-by":"publisher","unstructured":"Chavada R, Ghosh N, Sandaradura I, Maley M, Van Hal SJ (2017) Establishment of an AUC0-24 threshold for nephrotoxicity is a step towards individualized vancomycin dosing for methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 61. \n                    https:\/\/doi.org\/10.1128\/AAC.02535-16","DOI":"10.1128\/AAC.02535-16"},{"key":"2694_CR15","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1128\/AAC.01708-10","volume":"55","author":"JA Roberts","year":"2011","unstructured":"Roberts JA, Taccone FS, Udy AA, Vincent JL, Jacobs F, Lipman J (2011) Vancomycin dosing in critically ill patients: robust methods for improved continuous-infusion regimens. Antimicrob Agents Chemother 55:2704\u20132709","journal-title":"Antimicrob Agents Chemother"},{"key":"2694_CR16","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1093\/jac\/dkp085","volume":"63","author":"AH Thomson","year":"2009","unstructured":"Thomson AH, Staatz CE, Tobin CM, Gall M, Lovering AM (2009) Development and evaluation of vancomycin dosage guidelines designed to achieve new target concentrations. J Antimicrob Chemother 63:1050\u20131057","journal-title":"J Antimicrob Chemother"},{"key":"2694_CR17","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/j.1365-2710.2006.00762.x","volume":"31","author":"P Llopis-Salvia","year":"2006","unstructured":"Llopis-Salvia P, Jimenez-Torres NV (2006) Population pharmacokinetic parameters of vancomycin in critically ill patients. J Clin Pharm Ther 31:447\u2013454","journal-title":"J Clin Pharm Ther"},{"key":"2694_CR18","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s40262-014-0164-z","volume":"53","author":"O Mangin","year":"2014","unstructured":"Mangin O, Urien S, Mainardi JL, Fagon JY, Faisy C (2014) Vancomycin pharmacokinetic and Pharmacodynamic models for critically ill patients with post-sternotomy mediastinitis. Clin Pharmacokinet 53:849\u2013861","journal-title":"Clin Pharmacokinet"},{"key":"2694_CR19","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1111\/j.1365-2710.2008.01016.x","volume":"34","author":"M Yamamoto","year":"2009","unstructured":"Yamamoto M, Kuzuya T, Baba H, Yamada K, Nabeshima T (2009) Population pharmacokinetic analysis of vancomycin in patients with gram-positive infections and the influence of infectious disease type. J Clin Pharm Ther 34:473\u2013483","journal-title":"J Clin Pharm Ther"},{"key":"2694_CR20","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1177\/0310057X1804600405","volume":"46","author":"D Tsai","year":"2018","unstructured":"Tsai D, Stewart PC, Hewagama S, Krishnaswamy S, Wallis SC, Lipman J, Roberts JA (2018) Optimised dosing of vancomycin in critically ill indigenous Australian patients with severe sepsis. Anaesth Intensive Care 46:374\u2013380","journal-title":"Anaesth Intensive Care"},{"key":"2694_CR21","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1111\/j.1365-2125.2005.02547.x","volume":"61","author":"CE Staatz","year":"2006","unstructured":"Staatz CE, Byrne C, Thomson AH (2006) Population pharmacokinetic modelling of gentamicin and vancomycin in patients with unstable renal function following cardiothoracic surgery. Br J Clin Pharmacol 61:164\u2013176","journal-title":"Br J Clin Pharmacol"},{"key":"2694_CR22","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/j.1365-2125.2010.03679.x","volume":"70","author":"N Revilla","year":"2010","unstructured":"Revilla N, Martin-Suarez A, Perez MP, Gonzalez FM, de Gatta MDF (2010) Vancomycin dosing assessment in intensive care unit patients based on a population pharmacokinetic\/pharmacodynamic simulation. Br J Clin Pharmacol 70:201\u2013212","journal-title":"Br J Clin Pharmacol"},{"key":"2694_CR23","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/phar.1531","volume":"35","author":"ED Adane","year":"2015","unstructured":"Adane ED, Herald M, Koura F (2015) Pharmacokinetics of vancomycin in extremely obese patients with suspected or confirmed Staphylococcus aureus infections. Pharmacotherapy 35:127\u2013139","journal-title":"Pharmacotherapy"},{"key":"2694_CR24","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1128\/AAC.01602-07","volume":"52","author":"TP Lodise","year":"2008","unstructured":"Lodise TP, Lomaestro B, Graves J, Drusano GL (2008) Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 52:1330\u20131336","journal-title":"Antimicrob Agents Chemother"},{"key":"2694_CR25","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1128\/AAC.01568-12","volume":"57","author":"SJ van Hal","year":"2013","unstructured":"van Hal SJ, Paterson DL, Lodise TP (2013) Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrob Agents Chemother 57:734\u2013744","journal-title":"Antimicrob Agents Chemother"},{"key":"2694_CR26","doi-asserted-by":"publisher","first-page":"3950","DOI":"10.1128\/AAC.00337-06","volume":"50","author":"VH Tam","year":"2006","unstructured":"Tam VH, Kabbara S, Yeh RF, Leary RH (2006) Impact of sample size on the performance of multiple-model pharmacokinetic simulations. Antimicrob Agents Chemother 50:3950\u20133952","journal-title":"Antimicrob Agents Chemother"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-019-02694-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-019-02694-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-019-02694-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,30]],"date-time":"2020-05-30T23:32:01Z","timestamp":1590881521000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-019-02694-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,1]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["2694"],"URL":"https:\/\/doi.org\/10.1007\/s00228-019-02694-1","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,1]]},"assertion":[{"value":"28 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"No authors report any relevant conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Waiver of informed consent was granted by the local ethics committee (CAAE 62009816.9.0000.0104).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}]}}